Immuneering Corporation (IMRX)
2.01
0.06 (3.08%)
At close: Jan 15, 2025, 11:54 AM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
| Year | FY23 | FY22 | FY21 | FY20 | FY19 |
| Revenue | n/a | 316.95K | 2.08M | 2.31M | 1.92M |
| Cost of Revenue | 764.14K | 158.12K | 1.15M | 1.28M | 1.22M |
| Gross Profit | -764.14K | 158.83K | 926.89K | 1.03M | 696.74K |
| Operating Income | -58.41M | -51.74M | -33.89M | -17.08M | -6.29M |
| Interest Income | 3.61M | 1.01M | 169.90K | 42.66K | 57.66K |
| Pretax Income | -53.47M | -50.51M | -33.84M | -17.04M | -7.71M |
| Net Income | -53.47M | -49.28M | -33.54M | -17.04M | -8.06M |
| Selling & General & Admin | 16.25M | 15.61M | 8.27M | 3.11M | 2.71M |
| Research & Development | 41.40M | 36.27M | 26.54M | 15.00M | 4.28M |
| Other Expenses | n/a | 30.05K | -127.06K | n/a | n/a |
| Operating Expenses | 57.65M | 51.90M | 34.81M | 18.11M | 6.99M |
| Interest Expense | n/a | 1.01M | n/a | n/a | 351.30K |
| Selling & Marketing Expenses | -511.87K | n/a | n/a | n/a | n/a |
| Cost & Expenses | 58.41M | 52.06M | 35.97M | 19.39M | 8.21M |
| Income Tax | n/a | -1.23M | -307.49K | -84.34K | 351.30K |
| Shares Outstanding (Basic) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| Shares Outstanding (Diluted) | 28.42M | 26.39M | 26.32M | 25.51M | 25.51M |
| EPS (Basic) | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EPS (Diluted) | -1.88 | -1.87 | -1.27 | -0.67 | -0.32 |
| EBITDA | -58.06M | -51.47M | -33.68M | -17.00M | -7.34M |
| Depreciation & Amortization | 352.08K | 796.79K | 159.07K | 79.31K | 18.08K |